Attenuation of portal hypertension by natural taurine in rats with liver cirrhosis

World Journal of Gastroenterology

Volumn 15, Issue 36, 2009, Pages 4529-4537

  Liang, Jian ^a   Deng, Xin ^a   Lin, Zhi Xiu ^b   Zhao, Li Chun ^a   Zhang, Xi Liu ^c  

^a Guangxi College of Traditional Chinese Medicine   (China)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c GUANGXI UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Liver cirrhosis; Portal hypertension; Rat; Taurine

Indexed keywords

2 AMINOETHYLSULFONIC ACID; COLLAGEN TYPE 1; COLLAGEN TYPE 3; CYCLIC GMP; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; TAURINE DERIVATIVE; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; HISTOPATHOLOGY; LIVER CIRRHOSIS; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PORTAL HYPERTENSION; PORTAL VEIN BLOOD FLOW; PORTAL VEIN BLOOD PRESSURE; PROTEIN EXPRESSION; RAT; SPLANCHNIC BLOOD FLOW;

ANIMALS; BIOMECHANICS; COLLAGEN TYPE I; COLLAGEN TYPE III; CYCLIC GMP; HEMODYNAMICS; HEPATIC STELLATE CELLS; HYPERTENSION, PORTAL; LIVER CIRRHOSIS, EXPERIMENTAL; MALE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; RATS; RATS, WISTAR; TAURINE; TRANSFORMING GROWTH FACTOR BETA;

EID: 71749093503     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.15.4529     Document Type: Article

References (34)

1. Bruha R, Petrtyl J, Urbanek P, Svestka T, Kalab M, Marecek Z. [Long-term pharmacological treatment of portal hypertension] Cas Lek Cesk 2005; 144 Suppl 1: 63-66
2. Hassoun Z, Pomier-Layrargues G. The transjugular intrahepatic portosystemic shunt in the treatment of portal hypertension. Eur J Gastroenterol Hepatol 2004; 16: 1-4 (Pubitemid 39043695)
3. Liang J, Deng X, WU JY, Yang GY, Huang RB. The effect of natural taurine on hepatic stellate cell of rat. Guangxi Yixue 2006; 28: 35-37
4. Reynaert H, Thompson MG, Thomas T, Geerts A. Hepatic stellate cells: role in microcirculation and pathophysiology of portal hypertension. Gut 2002; 50: 571-581 (Pubitemid 34638880)
5. Safadi R, Friedman SL. Hepatic fibrosis - role of hepatic stellate cell activation. MedGenMed 2002; 4: 27
6. Wang YK, Chi BR, Sun B, Wang ZC. Establishment and stability of hepatic cirrhosis rat models. Jilin Daxue Xuebao (Yixue ban) 2005; 31: 893-895 (Pubitemid 43033820)
7. Shi B, Zhu L, Zhang ZB, Xie WF, Wu GQ, Liu BY, Chao YX. The changes of biomechanical properties of the portal veins in the rats during the pathogenesis of intrahepatic portal hypertension. J Med Biomech 2004; 19: 228-232
8. Brunt EM. Grading and staging the histological lesions of chronic hepatitis: the Knodell histology activity index and beyond. Hepatol 2000; 31: 241-246
9. Hunt N, Fleming K. Reproducibility of liver biopsy grading and staging. Liver 1999; 19: 169-170 (Pubitemid 29261580)
10. Marie CB, Mathieu O, Guillaume Q, Maxim M. Taurine-deficient dilated cardiomyopathy in a family of golden retrievers. J Am Anim Hosp Assoc 2005; 41: 284-291
11. Robert CB, Kwang SK, Andrea JF, Mark DK, Kittleson KA, MacDonald DJ, Maggs JB, Quinton RR. Low plasma taurine concentration in Newfoundland dog is associated with low plasma methionine and cyst(e)ine concentrations and low taurine synthesis. J Nutr 2006; 136: 2525-2533
12. Yildirim Z, Kilic N, Ozer C, Babul A, Take G, Erdogan D. Effects of taurine in cellular responses to oxidative stress in young and middle-aged rat liver. Ann N Y Acad Sci 2007; 1100: 553-561 (Pubitemid 47092695)
13. Morales I, Dopico JG, Sabate M, Gonzalez-Hernandez T, Rodriguez M. Substantia nigra osmoregulation: taurine and ATP involvement. Am J Physiol Cell Physiol 2007; 292: C1934-C1941 (Pubitemid 47080579)
14. Hosoi M, Takeuchi K, Sawada H, Toyohara H. Expression and functional analysis of mussel taurine transporter, as a key molecule in cellular osmoconforming. J Exp Biol 2005; 208: 4203-4211 (Pubitemid 41789746)
15. Tabassum H, Parvez S, Rehman H, Dev Banerjee B, Siemen D, Raisuddin S. Nephrotoxicity and its prevention by taurine in tamoxifen induced oxidative stress in mice. Hum Exp Toxicol 2007; 26: 509-518 (Pubitemid 47218493)
16. Bianchi L, Colivicchi MA, Ballini C, Fattori M, Venturi C, Giovannini MG, Healy J, Tipton KF, Della Corte L. Taurine, taurine analogues, and taurine functions: overview. Adv Exp Med Biol 2006; 583: 443-448
17. Razvodovskii IuE, Doroshenko EM, Prokopchik NI, Smirnov VIu, Ostrovskii SIu. [Hepatoprotective effects of amino acids with branched hydrocarbon chains and taurine in experimental subchronic alcohol intoxication and ethanol withdrawal] Biomed Khim 2004; 50: 64-72
18. Warskulat U, Borsch E, Reinehr R, Heller-Stilb B, Monnighoff I, Buchczyk D, Donner M, Flogel U, Kappert G, Soboll S, Beer S, Pfeffer K, Marschall HU, Gabrielsen M, Amiry-Moghaddam M, Ottersen OP, Dienes HP, Haussinger D. Chronic liver disease is triggered by taurine transporter knockout in the mouse. FASEB J 2006; 20: 574-576 (Pubitemid 46671254)
19. Chen YX, Zhang XR, Xie WF, Li S. Effects of taurine on proliferation and apoptosis of hepatic stellate cells in vitro. Hepatobiliary Pancreat Dis Int 2004; 3: 106-109 (Pubitemid 38256137)
20. Miyazaki T, Karube M, Matsuzaki Y, Ikegami T, Doy M, Tanaka N, Bouscarel B. Taurine inhibits oxidative damage and prevents fibrosis in carbon tetrachloride-induced hepatic fibrosis. J Hepatol 2005; 43: 117-125 (Pubitemid 40805282)
21. Liang J, Deng X, Yang GY, Huang RB, Pang YS. Study on the effect of natural taurine in hepatic fibrosis of tissue and serum. Guangxi Zhongyi Xueyuan Xuebao 2006; 9: 2-4
22. Liang J, Deng X, WU JY, Yang GY, Huang RB. Effect of taurine at hepatic stellate cell on portal hypertension. Guangxi Yixue 2006; 28: 5-7
23. Montano-Loza A, Meza-Junco J. [Pathogenesis of portal hypertension] Rev Invest Clin 2005; 57: 596-607
24. Moreau R, Lebrec D. Molecular and structural basis of portal hypertension. Clin Liver Dis 2006; 10: 445-457, vii
25. Groszmann RJ, Abraldes JG. Portal hypertension: from bedside to bench. J Clin Gastroenterol 2005; 39: S125-S130
26. Reichen J, Lebrec D. The future treatment of portal hypertension. Best Pract Res Clin Gastroenterol 2007; 21: 191-202
27. Shams V, Erkan T, Gumustas MK, Cullu F, Kutlu T, Kaya H, Aydin S, Tumay G. The role of nitric oxide in pediatric patients with portal hypertension. J Trop Pediatr 2003; 49: 33-36 (Pubitemid 36277628)
28. Shah V. Cellular and molecular basis of portal hypertension. Clin Liver Dis 2001; 5: 629-644 (Pubitemid 32847053)
29. Rockey DC. Hepatic fibrosis, stellate cells, and portal hypertension. Clin Liver Dis 2006; 10: 459-479, vii-viii
30. Li J, Niu JZ, Wang JF, Li Y, Tao XH. Pathological mechanisms of alcohol-induced hepatic portal hypertension in early stage fibrosis rat model. World J Gastroenterol 2005; 11: 6483-6488 (Pubitemid 43136885)
31. Gressner AM, Weiskirchen R, Breitkopf K, Dooley S. Roles of TGF-beta in hepatic fibrosis. Front Biosci 2002; 7: d793-d807
32. Gressner AM, Weiskirchen R. Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. J Cell Mol Med 2006; 10: 76-99 (Pubitemid 44874293)
33. Shi B, Zhu L, Zhang ZB, Xie WF, Wu GQ, Liu BY, Chao YX. The changes of biomechanical properties of the portal veins in the rats during the pathogenesis of intrahepatic portal hypertension. J Med Biomech 2004; 19: 228-233
34. Li T, Yang Z. Research progress of vasculopathy in portal hypertension. World J Gastroenterol 2005; 11: 6079-6084 (Pubitemid 43085045)